申请人:Janssen Pharmaceutica NV
公开号:US20220009906A1
公开(公告)日:2022-01-13
The present invention is directed to isoindolin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including, but not limited to, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, end stage chronic kidney disease, kidney failure, etc.
本发明涉及异吲哚啉-1-酮衍生物,包含它们的药物组合物以及它们在治疗由GRK2调节的疾病和状况中的用途,包括但不限于心力衰竭、心肌肥大、高血压、Ⅱ型糖尿病、NASH、NAFLD、晚期慢性肾脏疾病、肾功能衰竭等。